Obinutuzumab

Drug Profile

Obinutuzumab

Alternative Names: Afutuzumab; GA 101; Gazyva; Gazyvaro; R 7159; RG 7159; RG 7195; RO 5072759

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator GLYCART Biotechnology
  • Developer Biogen Idec; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Genentech; M. D. Anderson Cancer Center; Nippon Shinyaku; OHSU Knight Cancer Institute; Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II CNS cancer; Follicular lymphoma; Lupus nephritis; Mantle-cell lymphoma
  • Discontinued Primary biliary cirrhosis

Most Recent Events

  • 07 Feb 2017 Registered for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in Canada (IV)
  • 11 Jan 2017 Genentech collaborates with NCI Formulary to co-develop obinutuzumab in Cancer
  • 03 Jan 2017 OHSU Knight Cancer Institute and National Cancer Institute plan a phase I/II trial for Chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma, Follicular lymphoma, Waldenstrom's macroglobulinaemia and Mantle cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03010358)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top